MedTrace Logo

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

NCT07080242 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-05-22

No results posted yet for this study

Summary

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Conditions

  • Small Cell Lung Cancer Metastatic or Locally Advanced
  • Neuroendocrine Cancer
  • Metastatic Neuroendocrine Prostate Cancer
  • Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
  • Metastatic Advanced Merkel Cell Carcinoma
  • Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung
  • Locally Advanced Extrapulmonary Neuroendocrine Carcinoma
  • Locally Advanced Neuroendocrine Prostate Cancer
  • Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine
  • Locally Advanced Merkel Cell Carcinoma
  • Metastatic Large Cell Neuroendocrine Carcinoma of the Lung

Interventions

DRUG

BL-M14D1

BL-M14D1 will be administered on D1 every 3 weeks.

Sponsors & Collaborators

  • SystImmune Inc.

    lead INDUSTRY

Principal Investigators

  • Rishi Jain · SystImmune Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07080242 on ClinicalTrials.gov